Avantor, Inc. announced the appointment of Simon Dingemans to its Board of Directors, effective January 2, 2026. Simon Dingemans is an accomplished executive with extensive global leadership experience across healthcare, finance and strategic business transformation. He was previously the Chief Financial Officer of GlaxoSmithKline plc, a Partner at Goldman Sachs, and a Managing Director at The Carlyle Group.
He currently serves on the boards of Vodafone Group Plc, WPP plc and Genomics LTD, where he is also non-executive Chair. Earlier in his career, Mr. Dingemans held senior leadership positions at Goldman Sachs International, where he oversaw UK investment banking and European mergers activity, and later served in senior advisory and operating roles at The Carlyle Group. He holds both a bachelor's degree and a master's degree in geography from the University of Oxford.
Mr. Dingemans, age 62, most recently served in senior leadership roles at The Carlyle Group, a global investment management firm, as Senior Advisor from 2022 to 2024 and as Managing Director and Partner, UK Buyouts from 2020 to 2022. Prior to his roles at The Carlyle Group, Mr. Dingemans served as the Chief Financial Officer of GSK plc, a global biopharmaceutical company, from 2011 to 2019. Mr. Dingemans also served in a variety of positions at Goldman Sachs, a global investment banking, securities and investment management firm, from 1995 to 2010, including Partner and held leadership roles overseeing the UK Investment Banking and European Mergers from 2000 to 2010, and Managing Director from 1995 to 2000.
Prior to Goldman Sachs, Mr. Dingemans spent ten years at SG Warburg, an investment bank, in positions of increasing responsibility. He currently serves on the boards of directors of Vodafone Group Plc, WPP plc and Genomics Limited. Mr. Dingemans holds both a master?s degree and a bachelor?s degree in geography from the University of Oxford.
Avantor, Inc. is a life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. The Company’s segments include Laboratory Solutions and Bioscience Production. Within its segments, it sells materials and consumables, equipment and instrumentation and services and specialty procurement to customers in the biopharma and healthcare, education and government and advanced technologies and applied materials industries. Materials and consumables include ultra-high purity chemicals and reagents, lab products and supplies, highly specialized formulated silicone materials, customized excipients, and others. Equipment and instrumentation include filtration systems, virus inactivation systems, incubators, analytical instruments, and others. Services and specialty procurement include onsite lab and production, equipment, procurement and sourcing and biopharmaceutical material scale-up and development services.
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.